A carregar...
Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin
BACKGROUND: The sodium-glucose co-transporter-2 (SGLT-2) inhibitors have been reported to increase both low-density lipoprotein (LDL) and high-density lipoprotein (HDL)-cholesterol (C). This study aimed to determine how SGLT-2 inhibitors affect LDL and HDL-C subspecies. METHODS: This single center,...
Na minha lista:
| Publicado no: | Cardiovasc Diabetol |
|---|---|
| Main Authors: | , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BioMed Central
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5237208/ https://ncbi.nlm.nih.gov/pubmed/28086872 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12933-016-0491-5 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|